LoadingLoadingLoadingNet selling: insiders sold $4.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $1K to $15K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Sells (1)
Top-trader positions in BBIO could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.64 expected
Estimates as of Oct 23, 2026
EPS expected
-$0.66 to -$0.40
Revenue expected
18 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$0.78 / -$0.64Alpha Vantage | -21.88% miss | $243.7M No estimateSEC filing | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$0.84 / -$0.62Alpha Vantage | -35.48% miss | $194.5M No estimateSEC filing | Unavailable |
| Dec 31, 2025 | Feb 24, 2026 | -$0.94 / -$0.72Alpha Vantage | -31.13% miss | $154.2M No estimate | Unavailable |
| Sep 30, 2025 | Oct 29, 2025 | -$0.72 / -$0.78Alpha Vantage | +7.69% beat | $120.7M No estimateSEC filing | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | -$0.95 / -$0.60Alpha Vantage | -58.33% miss | $110.6M No estimateSEC filing | Unavailable |
| Mar 31, 2025 | Apr 29, 2025 | -$0.99 / -$0.89Alpha Vantage | -11.10% miss | $116.6M No estimateSEC filing | Unavailable |
| Dec 31, 2024 | Feb 20, 2025 | -$1.37 / -$1.09Alpha Vantage | -26.09% miss | $5.9M No estimate | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | -$0.86 / -$0.98Alpha Vantage | +12.29% beat | $2.7M No estimateSEC filing | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $120.7M | $154.2M | $194.5M | $243.7M |
| Cost of what it sold | $6.6M | $15.4M | $10.4M | $15.0M |
| Gross profit | $114.1M | $138.8M | $184.1M | $228.6M |
| What it spent | ||||
| Research and development | $112.9M | $142.0M | $126.6M | $149.4M |
| Sales and admin | $137.6M | $158.1M | $163.9M | $186.3M |
| Other operating costs | $8.8M | $23.9M | — | — |
| Total operating expenses | $259.3M | $324.0M | $290.0M | $335.7M |
| What was left | ||||
| Operating profit | -$145.2M | -$185.2M | -$106.0M | -$107.1M |
| Interest on debt | $11.7M | $12.0M | $52.8M | $13.3M |
| Profit before tax | -$186.5M | -$197.2M | -$166.6M | -$155.9M |
| Tax | -$1.5M | — | — | -$6.2M |
| Net profit | -$182.7M | -$197.2M | -$164.0M | -$152.2M |
| EBITDA | -$173.3M | -$183.8M | -$112.6M | -$141.6M |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Citigroup cuts target for BridgeBio Pharma stock to USD 91.00
Leans bearishOct 20BridgeBio Pharma (BBIO) Draws Fresh Attention, Is The Pullback A Valuation Opportunity?
NeutralOct 20BridgeBio Pharma (BBIO) Advances Late Stage Programs, Is The Valuation Still Pricey?
NeutralOct 20Lobbying Update: $510,000 of BRIDGEBIO PHARMA INC. lobbying was just disclosed
NeutralOct 20BBIO Maintains Rating by Citigroup -- Price Target Lowered to $9
NeutralOct 19BBIO Maintained by Piper Sandler -- Price Target Raised to $120
Leans bullishOct 19BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
Leans bearishOct 19BRIDGEBIO PHARMA, INC. : BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $102 FROM $104
Leans bearishOct 19
